Results from phase 3 gene therapy trial for diabetic peripheral...

VM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy. The Phase 3 study for painful DPN, led by Professor John (Jack)...(PRWeb January 20, 2021)Read the full story at https://www.prweb.com/releases/results_from_phase_3_gene_therapy_trial_for_diabetic_peripheral_neuropathy_published_online_by_clinical_and_translational_science/prweb17672785.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news